Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
BIOMARKER:
MPZL3 overexpression
i
Other names:
MPZL3, Myelin Protein Zero Like 3, Myelin Protein Zero-Like Protein 3
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Entrez ID:
196264
Associations
News
Trials
VERI cancer hierarchy
Reset Filters
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
inavolisib
Resistant: D – Preclinical
inavolisib
Resistant
:
D
inavolisib
Resistant: D – Preclinical
inavolisib
Resistant
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
fulvestrant
Resistant: D – Preclinical
fulvestrant
Resistant
:
D
fulvestrant
Resistant: D – Preclinical
fulvestrant
Resistant
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
AZD9496
Resistant: D – Preclinical
AZD9496
Resistant
:
D
AZD9496
Resistant: D – Preclinical
AZD9496
Resistant
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
STA-4783
Resistant: D – Preclinical
STA-4783
Resistant
:
D
STA-4783
Resistant: D – Preclinical
STA-4783
Resistant
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
SR16157
Resistant: D – Preclinical
SR16157
Resistant
:
D
SR16157
Resistant: D – Preclinical
SR16157
Resistant
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
midostaurin
Sensitive: D – Preclinical
midostaurin
Sensitive
:
D
midostaurin
Sensitive: D – Preclinical
midostaurin
Sensitive
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
DFN-529
Sensitive: D – Preclinical
DFN-529
Sensitive
:
D
DFN-529
Sensitive: D – Preclinical
DFN-529
Sensitive
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
pyrotinib
Sensitive: D – Preclinical
pyrotinib
Sensitive
:
D
pyrotinib
Sensitive: D – Preclinical
pyrotinib
Sensitive
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
paclitaxel
Resistant: D – Preclinical
paclitaxel
Resistant
:
D
paclitaxel
Resistant: D – Preclinical
paclitaxel
Resistant
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
TKI258
Sensitive: D – Preclinical
TKI258
Sensitive
:
D
TKI258
Sensitive: D – Preclinical
TKI258
Sensitive
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
AZD0530
Sensitive: D – Preclinical
AZD0530
Sensitive
:
D
AZD0530
Sensitive: D – Preclinical
AZD0530
Sensitive
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
vandetanib
Sensitive: D – Preclinical
vandetanib
Sensitive
:
D
vandetanib
Sensitive: D – Preclinical
vandetanib
Sensitive
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
erlotinib
Sensitive: D – Preclinical
erlotinib
Sensitive
:
D
erlotinib
Sensitive: D – Preclinical
erlotinib
Sensitive
:
D
MPZL3 overexpression
Breast Cancer
MPZL3 overexpression
Breast Cancer
lapatinib
Sensitive: D – Preclinical
lapatinib
Sensitive
:
D
lapatinib
Sensitive: D – Preclinical
lapatinib
Sensitive
:
D
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login